Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis

Cancer Cell

Volumn 3, Issue 3, 2003, Pages 219-231

  Watnick, Randolph S ^a   Cheng, Yi Ning ^b   Rangarajan, Annapoorni ^a   Ince, Tan A ^a,c   Weinberg, Robert A ^a,b  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; MYC PROTEIN; ONCOPROTEIN; PROTEIN KINASE; RAS PROTEIN; RHO FACTOR; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; UO 126; VIRUS PROTEIN; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SERINE THREONINE KINASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE; RHO-ASSOCIATED KINASE; SIGNAL PEPTIDE; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; BIOENGINEERING; BREAST CANCER; CANCER CELL; CARCINOGENESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; GENE REPRESSION; HUMAN; KIDNEY CELL; NONHUMAN; ONCOGENE; ONCOGENE H RAS; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SIMIAN VIRUS 40; TUMOR; WESTERN BLOTTING; BIOLOGICAL MODEL; CELL LINE; CELL TRANSPLANTATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; TUMOR SUPPRESSOR GENE; XENOGRAFT;

SIMIAE; SIMIAN VIRUS 40;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE; CELL LINE, TRANSFORMED; CELL TRANSPLANTATION; ENDOTHELIAL GROWTH FACTORS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; GENES, TUMOR SUPPRESSOR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-SERINE-THREONINE KINASES; RAS PROTEINS; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; THROMBOSPONDIN 1; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0042972556     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00030-8     Document Type: Article

References (79)

1. Amano M., Ito M., Kimura K., Fukata Y., Chihara K., Nakano T., Matsuura Y., Kaibuchi K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J. Biol. Chem. 271:1996;20246-20249.
2. Artandi S.E., DePinho R.A. Mice without telomerase. what can they teach us about human cancer? Nat. Med. 6:2000;852-855.
3. Berse B., Brown L.F., Van de Water L., Dvorak H.F., Senger D.R. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages and tumors. Mol. Biol. Cell. 3:1992;211-220.
4. Blackwood E.M., Eisenman R.N. Max. a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc Science. 251:1991;1211-1217.
5. Blasco M.A. Telomerase beyond telomeres. Nat. Rev. Cancer. 2:2002;627-633.
6. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., Harley C.B., Shay J.W., Lichtsteiner S., Wright W.E. Extension of life-span by introduction of telomerase into normal human cells. Science. 279:1998;349-352.
7. Brown L.F., Guidi A.J., Schnitt S.J., Van de Water L., Iruela-Arispe M.L., Yeo T.K., Tognazzi K., Dvorak H.F. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin. Cancer Res. 5:1999;1041-1056.
8. Castle V., Varani J., Fligiel S., Prochownik E.V., Dixit V. Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma. J. Clin. Invest. 87:1991;1883-1888.
9. Cavallaro U., Christofori G. Molecular mechanisms of tumor angiogenesis and tumor progression. J. Neurooncol. 50:2000;63-70.
10. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., Shen Q., O'Hagan R., Pantginis J., Zhou H., et al. Essential role for oncogenic Ras in tumor maintenance. Nature. 400:1999;468-472.
11. Clark E.A., Golub T.R., Lander E.S., Hynes R.O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 406:2000;532-535.
12. Coussens L.M., Raymond W.W., Bergers G., Laig-Webster M., Behrendtsen O., Werb Z., Caughey G.H., Hanahan D. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13:1999;1382-1397.
13. Dawson D.W., Pearce S.F., Zhong R., Silverstein R.L., Frazier W.A., Bouck N.P. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138:1997;707-717.
14. Elenbaas B., Spirio L., Koerner F., Fleming M.D., Zimonjic D.B., Donaher J.L., Popescu N.C., Hahn W.C., Weinberg R.A. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15:2001;50-65.
15. Escot C., Theillet C., Lidereau R., Spyratos F., Champeme M.H., Gest J., Callahan R. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc. Natl. Acad. Sci. USA. 83:1986;4834-4838.
16. Favata M.F., Horiuchi K.Y., Manos E.J., Daulerio A.J., Stradley D.A., Feeser W.S., Van Dyk D.E., Pitts W.J., Earl R.A., Hobbs F., et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273:1998;18623-18632.
17. Folkman J. Tumor angiogenesis. Adv. Cancer Res. 43:1985;175-203.
18. Framson P., Bornstein P. A serum response element and a binding site for NF-Y mediate the serum response of the human thrombospondin 1 gene. J. Biol. Chem. 268:1993;4989-4996.
19. Franke T.F., Yang S.I., Chan T.O., Datta K., Kazlauskas A., Morrison D.K., Kaplan D.R., Tsichlis P.N. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell. 81:1995;727-736.
20. Good D.J., Polverini P.J., Rastinejad F., Le-Beau M.M., Lemons R.S., Frazier W.A., Bouck N.P. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA. 87:1990;6624-6628.
21. Guo N., Krutzsch H.C., Inman J.K., Roberts D.D. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res. 57:1997;1735-1742.
22. Gupta S., Seth A., Davis R.J. Transactivation of gene expression by Myc is inhibited by mutation at the phosphorylation sites Thr-58 and Ser-62. Proc. Natl. Acad. Sci. USA. 90:1993;3216-3220.
23. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature. 400:1999;464-468.
24. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
25. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
26. Hanahan D., Christofori G., Naik P., Arbeit J. Transgenic mouse models of tumour angiogenesis. the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models Eur. J. Cancer. 32A:1996;2386-2393.
27. Henriksson M., Bakardjiev A., Klein G., Luscher B. Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene. 8:1993;3199-3209.
28. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of micrometastases. balanced proliferation and apoptosis in the presence of angiogenesis suppression Nat. Med. 1:1995;149-153.
29. Holsinger L.J., Spencer D.M., Austin D.J., Schreiber S.L., Crabtree G.R. Signal transduction in T lymphocytes using a conditional allele of Sos. Proc. Natl. Acad. Sci. USA. 92:1995;9810-9814.
30. Hoover R.R., Gerlach M.J., Koh E.Y., Daley G.Q. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene. 20:2001;5826-5835.
31. Hu G., Riordan J.F., Vallee B.L. Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc. Natl. Acad. Sci. USA. 91:1994;12096-12100.
32. Kawano Y., Fukata Y., Oshiro N., Amano M., Nakamura T., Ito M., Matsumura F., Inagaki M., Kaibuchi K. Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J. Cell Biol. 147:1999;1023-1038.
33. Kiyono T., Foster S.A., Koop J.I., McDougall J.K., Galloway D.A., Klingelhutz A.J. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature. 396:1998;84-88.
34. Kozma S.C., Bogaard M.E., Buser K., Saurer S.M., Bos J.L., Groner B., Hynes N.E. The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. Nucleic Acids Res. 15:1987;5963-5971.
35. Land H., Parada L.F., Weinberg R.A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 304:1983;596-602.
36. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309.
37. Leung T., Chen X.Q., Manser E., Lim L. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol. Cell. Biol. 16:1996;5313-5327.
38. Li L.H., Nerlov C., Prendergast G., MacGregor D., Ziff E.B. c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. EMBO J. 13:1994;4070-4079.
39. Li Q., Ahuja N., Burger P.C., Issa J.P. Methylation and silencing of the Thrombospondin-1 promoter in human cancer. Oncogene. 18:1999;3284-3289.
40. Little C.D., Nau M.M., Carney D.N., Gazdar A.F., Minna J.D. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature. 306:1983;194-196.
41. Littlewood T.D., Hancock D.C., Danielian P.S., Parker M.G., Evan G.I. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23:1995;1686-1690.
42. Lutterbach B., Hann S.R. Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol. Cell. Biol. 14:1994;5510-5522.
43. MacDougall J.R., Matrisian L.M. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev. 14:1995;351-362.
44. MacGregor D., Li L.H., Ziff E.B. Dominant negative mutants of Myc inhibit cooperation of both Myc and adenovirus serotype-5 E1a with Ras. J. Cell. Physiol. 167:1996;95-105.
45. Majack R.A., Mildbrandt J., Dixit V.M. Induction of thrombospondin messenger RNA levels occurs as an immediate primary response to platelet-derived growth factor. J. Biol. Chem. 262:1987;8821-8825.
46. Matsui T., Amano M., Yamamoto T., Chihara K., Nakafuku M., Ito M., Nakano T., Okawa K., Iwamatsu A., Kaibuchi K. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 15:1996;2208-2216.
47. Mitchell K.O., El Deiry W.S. Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol- 13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ. 10:1999;223-230.
48. Nau M.M., Carney D.N., Battey J., Johnson B., Little C., Gazdar A., Minna J.D. Amplification, expression and rearrangement of c-myc and N-myc oncogenes in human lung cancer. Curr. Top. Microbiol. Immunol. 113:1984;172-177.
49. Ngo C.V., Gee M., Akhtar N., Yu D., Volpert O., Auerbach R., Thomas-Tikhonenko A. An in vivo function for the transforming Myc protein. elicitation of the angiogenic phenotype Cell Growth Differ. 11:2000;201-210.
50. Nguyen M., Watanabe H., Budson A.E., Richie J.P., Hayes D.F., Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. Natl. Cancer Inst. 86:1994;356-361.
51. Noguchi K., Kitanaka C., Yamana H., Kokubu A., Mochizuki T., Kuchino Y. Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase. J. Biol. Chem. 274:1999;32580-32587.
52. Olive P.L., Vikse C., Trotter M.J. Measurement of oxygen diffusion distance in tumor cubes using a fluorescent hypoxia probe. Int. J. Radiat. Oncol. Biol. Phys. 22:1992;397-402.
53. Olson M.F., Ashworth A., Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science. 269:1995;1270-1272.
54. O'Reilly M.S., Holmgren L., Chen C., Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2:1996;689-692.
55. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin. an endogenous inhibitor of angiogenesis and tumor growth Cell. 88:1997;277-285.
56. Pelengaris S., Khan M., Evan G.I. Suppression of myc-induced apoptosis in Beta cells exposes multiple oncogenic properties of myc and triggers carcinogenic progression. Cell. 109:2002;321-334.
57. Pulverer B.J., Fisher C., Vousden K., Littlewood T., Evan G., Woodgett J.R. Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene. 9:1994;59-70.
58. Rak J., Mitsuhashi Y., Bayko L., Filmus J., Shirasawa S., Sasazuki T., Kerbel R.S. Mutant ras oncogenes upregulate VEGF/VPF expression. implications for induction and inhibition of tumor angiogenesis Cancer Res. 55:1995;4575-4580.
59. Rak J., Mitsuhashi Y., Sheehan C., Tamir A., Viloria-Petit A., Filmus J., Mansour S.J., Ahn N.G., Kerbel R.S. Oncogenes and tumor angiogenesis. differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts Cancer Res. 60:2000;490-498.
60. Ramaswamy S., Nakamura N., Vazquez F., Batt D.B., Perera S., Roberts T.M., Sellers W.R. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA. 96:1999;2110-2115.
61. Ren X.D., Schwartz M.A. Determination of GTP loading on Rho. Methods Enzymol. 325:2000;264-272.
62. Ribatti D., Alessandri G., Vacca A., Iurlaro M., Ponzoni M. Human neuroblastoma cells produce extracellular matrix-degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo. Int. J. Cancer. 77:1998;449-454.
63. Ridley A.J. The GTP-binding protein Rho. Int. J. Biochem. Cell Biol. 29:1997;1225-1229.
64. Rodriguez-Manzaneque J.C., Lane T.F., Ortega M.A., Hynes R.O., Lawler J., Iruela-Arispe M.L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA. 98:2001;12485-12490.
65. Sahai E., Marshall C.J. ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat. Cell Biol. 4:2002;408-415.
66. Sahai E., Ishizaki T., Narumiya S., Treisman R. Transformation mediated by RhoA requires activity of ROCK kinases. Curr. Biol. 9:1999;136-145.
67. Sears R., Nuckolls F., Haura E., Taya Y., Tamai K., Nevins J.R. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14:2000;2501-2514.
68. Seshadri R., Matthews C., Dobrovic A., Horsfall D.J. The significance of oncogene amplification in primary breast cancer. Int. J. Cancer. 43:1989;270-272.
69. Seth A., Alvarez E., Gupta S., Davis R.J. A phosphorylation site located in the NH2-terminal domain of c-Myc increases transactivation of gene expression. J. Biol. Chem. 266:1991;23521-23524.
70. Singhal R.L., Yeh Y.A., Look K.Y., Sledge G.W., Weber G. Coordinated increase in activities of the signal transduction enzymes PI kinase and PIP kinase in human cancer cells. Life Sci. 55:1994;1487-1492.
71. Soncin F. Angiogenin supports endothelial and fibroblast cell adhesion. Proc. Natl. Acad. Sci. USA. 89:1992;2232-2236.
72. Staller P., Peukert K., Kiermaier A., Seoane J., Lukas J., Karsunky H., Moroy T., Bartek J., Massague J., Hanel F., Eilers M. Repression of p15INK4b expression by Myc through association with Miz-1. Nat. Cell Biol. 3:2001;392-399.
73. Tikhonenko A.T., Black D.J., Linial M.L. Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene. J. Biol. Chem. 271:1996;30741-30747.
74. Trent J., Meltzer P., Rosenblum M., Harsh G., Kinzler K., Mashal R., Feinberg A., Vogelstein B. Evidence for rearrangement, amplification, and expression of c-myc in a human glioblastoma. Proc. Natl. Acad. Sci. USA. 83:1986;470-473.
75. Uehata M., Ishizaki T., Satoh H., Ono T., Kawahara T., Morishita T., Tamakawa H., Yamagami K., Inui J., Maekawa M., Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 389:1997;990-994.
76. Vlahos C.J., Matter W.F., Hui K.Y., Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269:1994;5241-5248.
77. Volpert O.V., Pili R., Sikder H.A., Nelius T., Zaichuk T., Morris C., Shiflett C.B., Devlin M.K., Conant K., Alani R.M. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell. 2:2002;473-483.
78. Wen S., Stolarov J., Myers M.P., Su J.D., Wigler M.H., Tonks N.K., Durden D.L. PTEN controls tumor-induced angiogenesis. Proc. Natl. Acad. Sci. USA. 98:2001;4622-4627.
79. White M.A., Nicolette C., Minden A., Polverino A., Van-Aelst L., Karin M., Wigler M.H. Multiple Ras functions can contribute to mammalian cell transformation. Cell. 80:1995;533-541.